Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 29, 2017

DrugPatentWatch Database Preview

ARGATROBAN Drug Profile

« Back to Dashboard

What is the patent landscape for Argatroban, and when can generic versions of Argatroban launch?

Argatroban is a drug marketed by Fresenius Kabi Usa, Hospira Inc, Mylan Institutional, Hikma Pharm Co Ltd, Par Sterile Products, Pfizer, Teva Pharms Usa, Sandoz, and Eagle Pharms. and is included in ten NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ARGATROBAN is argatroban. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the argatroban profile page.

Summary for Tradename: ARGATROBAN

Patents:0
Applicants:9
NDAs:10
Suppliers / Packagers: see list5
Bulk Api Vendors: see list92
Clinical Trials: see list5
Patent Applications: see list3,748
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ARGATROBAN at DailyMed

Pharmacology for Tradename: ARGATROBAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa
ARGATROBAN
argatroban
INJECTABLE;INJECTION201811-001Mar 23, 2015APRXNoNo► Subscribe► Subscribe
Pfizer
ARGATROBAN
argatroban
INJECTABLE;INJECTION020883-001Jun 30, 2000APRXYesYes► Subscribe► Subscribe
Hikma Pharm Co Ltd
ARGATROBAN
argatroban
INJECTABLE;INJECTION203049-002Sep 30, 2016RXYesYes► Subscribe► Subscribe
Sandoz
ARGATROBAN IN SODIUM CHLORIDE
argatroban
INJECTABLE;IV (INFUSION)022485-001May 9, 2011RXYesYes► Subscribe► Subscribe
Teva Pharms Usa
ARGATROBAN IN 0.9% SODIUM CHLORIDE
argatroban
INJECTABLE;IV (INFUSION)206769-001Dec 15, 2014RXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot